Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$302.64+0.6%$292.49$200.63▼$377.46$6.68B-1.08357,018 shs271,306 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals+0.63%+6.94%+9.37%-6.59%+8.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDGLMadrigal Pharmaceuticals3.9165 of 5 stars3.40.00.04.61.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6338.99% UpsideCurrent Analyst Ratings BreakdownLatest MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal Pharmaceuticals$180.13M37.30N/AN/A$34.59 per share8.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)Latest MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.175.915.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals21.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableMDGL HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts4 hours ago | marketbeat.comMadrigal, Viking among notable gainers after Altimmune’s MASH setbackJune 26, 2025 | msn.comMadrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, RezdiffraJune 24, 2025 | msn.comMadrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA OutperformsJune 23, 2025 | seekingalpha.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Insider Trading ActivityJune 21, 2025 | benzinga.comEU regulator backs conditional authorisation for Madrigal's liver disease drugJune 20, 2025 | msn.comMadrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra ApprovalJune 20, 2025 | marketwatch.comEU medicines regulator grants conditional authorisation for Madrigal's liver disease drugJune 20, 2025 | msn.comMadrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver FibrosisJune 20, 2025 | finance.yahoo.comMadrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver FibrosisJune 20, 2025 | globenewswire.comMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | finanznachrichten.deMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)June 17, 2025 | globenewswire.comHandelsbanken Fonder AB Decreases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)June 15, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 6% - Should You Buy?June 11, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Acquired by Rhumbline AdvisersJune 11, 2025 | marketbeat.comCantor Fitzgerald Weighs in on MDGL FY2026 EarningsJune 10, 2025 | marketbeat.comRheos Capital Works Inc. Sells 13,000 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)June 9, 2025 | marketbeat.comGAMMA Investing LLC Has $12.95 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)June 7, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 6, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Has $3.65 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)June 5, 2025 | marketbeat.comMadrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care ConferenceJune 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL Company DescriptionsMadrigal Pharmaceuticals NASDAQ:MDGL$302.64 +1.89 (+0.63%) As of 06/30/2025 04:00 PM EasternMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
